Celon Pharma SA (8RP) Price & Analysis

2 Followers

8RP Stock Chart & Stats

€4.56

€0.03(0.66%)

At close: Jul 24 4:00 PM EDT

€4.56

€0.03(0.66%)

Day’s Range― - ―

52-Week Range€4.27 - €5.77

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€257.24M

Enterprise Value€1.10K

Total Cash (Recent Filing)€9.09M

Total Debt (Recent Filing)€53.68M

Price to Earnings (P/E)10.0

Beta0.54

Next Earnings

Sep 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.05

Shares Outstanding53,911,500

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)3.02

Price to Sales (P/S)5.22

P/FCF Ratio-35.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.6

Revenue Forecast (FY)€62.34M

Bulls Say, Bears Say

Bulls Say

Strong Gross Profit MarginA strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.

Low LeverageLow leverage provides financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant debt burden.

Revenue Growth PotentialHigh revenue growth potential indicates strong demand for products and successful market penetration, supporting long-term business expansion.

Bears Say

Negative Revenue GrowthNegative revenue growth suggests challenges in maintaining sales momentum, which can hinder long-term business sustainability and market competitiveness.

Profitability ChallengesOngoing profitability challenges indicate operational inefficiencies and may limit the company's ability to reinvest in growth and innovation.

Cash Flow Management IssuesPoor cash flow management can strain financial resources, limiting the company's ability to fund operations and strategic initiatives over the long term.

Celon Pharma SA News

Celon Pharma SA (8RP) Q4 Earnings Cheat Sheet

Celon Pharma SA (8RP) is scheduled to report 4th quarter earnings on 03/29/2023. Regarding Q4 estimates, Wall Street...

3y ago

8RP FAQ

What was Celon Pharma SA’s price range in the past 12 months?

Celon Pharma SA lowest stock price was €4.26 and its highest was €5.77 in the past 12 months.

What is Celon Pharma SA’s market cap?

Celon Pharma SA’s market cap is €257.24M.

When is Celon Pharma SA’s upcoming earnings report date?

Celon Pharma SA’s upcoming earnings report date is Sep 16, 2026 which is in 38 days.

How were Celon Pharma SA’s earnings last quarter?

Currently, no data Available

Is Celon Pharma SA overvalued?

According to Wall Street analysts Celon Pharma SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Celon Pharma SA pay dividends?

Celon Pharma SA does not currently pay dividends.

What is Celon Pharma SA’s EPS estimate?

Celon Pharma SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Celon Pharma SA have?

Celon Pharma SA has 53,911,500 shares outstanding.

What happened to Celon Pharma SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Celon Pharma SA?

Currently, no hedge funds are holding shares in DE:8RP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Celon Pharma SA

Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.